Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | NAAA | Q02083 | 2/20 | 0.62 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.49 |
| ▸ | GNAO1 | P09471 | 4/20 | 0.49 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.49 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | PRKCA | P17252 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8708433 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL8708430 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL8709259 | 1.00 | SMN1; SMN2 (0.68) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL19975925 | 0.92 | SMN1; SMN2 (0.59) | SMN1; SMN2NAAACHRM1 | |
| SCHEMBL29663742 | 0.91 | NAAA (0.71) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL17686363 | 0.91 | NAAA (0.71) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL26127863 | 0.91 | NAAA (0.71) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL31404784 | 0.91 | NAAA (0.71) | SMN1; SMN2NAAAGNAI3GNAO1GNAI1 | |
| SCHEMBL19975904 | 0.89 | SMN1; SMN2 (0.55) | SMN1; SMN2NAAA | |
| SCHEMBL7746812 | 0.87 | SMN1; SMN2 (0.62) | SMN1; SMN2NAAACHRM4CHRM5CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | claimed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | claimed |
| EP-0844000-A1 | Use of alpha, omega-diarylalkane derivatives in the treatment and prevention of psychosis | SANKYO COMPANY LIMITED (JP) | 1998-05-27 | — | — | EP | disclosed |
| US-5556864-A | TREATMENT OF CIRCULATORY DISEASES AND PSYCHOSIS | SANKYO COMPANY, LIMITED (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0600717-A1 | Phenoxyalkylamines, -pyrrolidines and -piperidines for the treatment and prevention of circulatory diseases and psychosis | SANKYO COMPANY LIMITED (JP) | 1994-06-08 | — | — | EP | disclosed |